Wells Fargo & Company Issues Positive Forecast for Pyxis Oncology (NASDAQ:PYXS) Stock Price

Pyxis Oncology (NASDAQ:PYXS) had its target price hoisted by Wells Fargo & Company from $12.00 to $19.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 392.23% from the stock’s current price.

Several other equities research analysts have also issued reports on PYXS. Weiss Ratings lowered shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Tuesday, August 18th. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Leerink Partners lowered their price objective on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, July 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pyxis Oncology presently has an average rating of “Moderate Buy” and an average target price of $8.38.

Pyxis Oncology Stock Down 0.8%

Pyxis Oncology stock traded down $0.03 during trading hours on Wednesday, hitting $3.86. The stock had a trading volume of 2,235,290 shares, compared to its average volume of 858,992. The company has a 50-day moving average of $3.00 and a two-hundred day moving average of $2.20. The company has a market cap of $321.95 million, a PE ratio of -2.74 and a beta of 1.34. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). As a group, analysts forecast that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Bank of America Corp DE boosted its holdings in shares of Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after acquiring an additional 9,062 shares in the last quarter. Acadian Asset Management LLC bought a new position in Pyxis Oncology in the 1st quarter valued at $81,000. XTX Topco Ltd acquired a new position in Pyxis Oncology in the second quarter worth $40,000. Marshall Wace LLP acquired a new position in Pyxis Oncology in the second quarter worth $163,000. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Pyxis Oncology by 128.4% during the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after purchasing an additional 57,935 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.